Brandon Griffin joins Advantar Labs

Appointed as vp of sales and marketing

Advantar Labs, a contract provider of GLP and GMP research, formulation development and small-scale clinical packaging services, has added Brandon Griffin to its senior management team as vp of sales and marketing.

The San Diego, California, US-based company has an aggressive expansion plan following triple-digit growth in 2010.

Griffin will head the planning, implementation and management of Advantar’s sales and marketing strategy.

He was previously western regional vp of sales at RohnerChem, a Switzerland-based CMO, heading sales for large-scale custom synthesis of small molecules and novel monomers/biopolymers in the US.

You may also like

Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Subscribe now